Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where P. R. Wilkins is active.

Publication


Featured researches published by P. R. Wilkins.


The Lancet | 2004

A novel and accurate diagnostic test for human African trypanosomiasis

Marios C. Papadopoulos; Paulo M. Abel; Dan Agranoff; August Stich; Edward Tarelli; B. Anthony Bell; Timothy Planche; Alison Loosemore; Samira Saadoun; P. R. Wilkins; Sanjeev Krishna

INTRODUCTION Human African trypanosomiasis (sleeping sickness) affects up to half a million people every year in sub-Saharan Africa. Because current diagnostic tests for the disease have low accuracy, we sought to develop a novel test that can diagnose human African trypanosomiasis with high sensitivity and specificity. METHODS We applied serum samples from 85 patients with African trypanosomiasis and 146 control patients who had other parasitic and non-parasitic infections to a weak cation exchange chip, and analysed with surface-enhanced laser desorption-ionisation time-of-flight mass spectrometry. Mass spectra were then assessed with three powerful data-mining tools: a tree classifier, a neural network, and a genetic algorithm. FINDINGS Spectra (2-100 kDa) were grouped into training (n=122) and testing (n=109) sets. The training set enabled data-mining software to identify distinct serum proteomic signatures characteristic of human African trypanosomiasis among 206 protein clusters. Sensitivity and specificity, determined with the testing set, were 100% and 98.6%, respectively, when the majority opinion of the three algorithms was considered. This novel approach is much more accurate than any other diagnostic test. INTERPRETATION Our report of the accurate diagnosis of an infection by use of proteomic signature analysis could form the basis for diagnostic tests for the disease, monitoring of response to treatment, and for improving the accuracy of patient recruitment in large-scale epidemiological studies.


Journal of Magnetic Resonance Imaging | 2004

Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy†

Kirstie S. Opstad; Mary M. Murphy; P. R. Wilkins; B. Anthony Bell; John R. Griffiths; Franklyn A. Howe

To determine if short echo time (TE) 1H magnetic resonance spectroscopy (MRS) can distinguish between intracranial metastases and glioblastomas.


British Journal of Neurosurgery | 2002

The contribution of proton magnetic resonance spectroscopy ( 1 HMRS) to clinical brain tumour diagnosis

M. Murphy; A. Loosemore; A. G. Clifton; Franklyn A. Howe; A.R. Tate; S. A. Cudlip; P. R. Wilkins; John R. Griffiths; B. A. Bell

Proton magnetic resonance spectroscopy ( 1 HMRS) provides biochemical information from tissue non-invasively, and has an evolving role in brain tumour diagnosis and management. We present 100 consecutive patients with brain tumours who had single voxel 1HMRS as part of their preoperative investigations. We report the histopathological findings and the diagnostic contribution of spectroscopy in an adjunctive role. On the basis of clinical and radiological information the preoperative diagnosis was unclear or inaccurate in 26 out of 100 cases. The discrepancy was of lesion grade in 17 cases and lesion type in 9 cases. In 6 of 100 patients with brain tumours 1HMRS could have made a significant contribution to the preoperative diagnosis if used as part of the routine assessment. There is therefore a useful role for 1HMRS in the evaluation of intracranial mass lesions.


International Journal of Radiation Oncology Biology Physics | 1999

Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration

Michael Brada; Geoffrey Sharpe; Balakrishnan Rajan; Juliet Britton; P. R. Wilkins; Douglas Guerrero; Frances Hines; Daphne Traish; Susan Ashley

PURPOSE To evaluate the efficacy and toxicity of accelerated radiotherapy in patients with primary high grade glioma, where acceleration is used as a means of delivering a shortened course of radical radiotherapy. PATIENTS AND METHODS Two-hundred and eleven patients with primary high grade glioma were treated at the Royal Marsden NHS Trust between 1987 and 1997 with accelerated radiotherapy (55 Gy in 34 fractions twice daily), to planning target volume (PTV) defined as enhancing tumour and a 3 cm margin. All had histologically confirmed high grade glioma (53 anaplastic astrocytoma, 137 glioblastoma multiforme, 4 gliosarcoma, 5 gemistocytic astrocytoma, 12 high grade astrocytoma not otherwise specified). The mean Karnofsky performance status (KPS) was 90 and median age was 54 years (range 19-77). RESULTS Of 211 patients entered, 201 were able to complete radiotherapy; 39 patients (19%) had deterioration in KPS during radiotherapy and this was transient in 11. Median survival of 211 patients was 10 months with 1 year, 2 year, and 3 year survival probabilities of 38%, 14%, and 8% respectively. Age and extent of excision were independent prognostic factors for survival. Previous comparison to matched cohort receiving 60 Gy in 30 daily fractions did not demonstrate significant survival difference. CONCLUSION Accelerated radiotherapy is a feasible treatment approach for patients with high grade glioma. The survival and functional outcome are comparable to conventional radiotherapy and the treatment is without serious acute toxicity. While acceleration of conventional dose irradiation could be tested in randomised studies, it is unlikely this approach would result in a clinically meaningful survival benefit. Accelerated radiotherapy therefore remains one of the ways of delivering radical irradiation in patients with high grade glioma. However, it adds complexity to what is a palliative treatment regimen and the rationale and advisability should be re-examined, particularly in terms of impact on quality of life, true patient preference, and health economic considerations.


Neurosurgery | 1993

Chondrosarcoma of the skull base: a series of eight cases.

S. R. Stapleton; P. R. Wilkins; Daniel J. Archer; David Uttley

Chondrosarcomas of the skull base are indolent, locally invasive tumors with a marked tendency to recur. Surgery is the mainstay of treatment because these tumors are generally resistant to other forms of treatment. A surgical approach with wide access to the skull base and one that is easily repeatable is required, because recurrence is common. We have used the LeFort I maxillotomy or mobilization of the zygoma at the time of craniotomy to obtain wide access to the skull base in eight cases of chondrosarcoma. Three patients have undergone subsequent procedures by us for recurrent disease. One patient died 30 days after the operation, and one has required an open repair of a cerebrospinal fluid leak. Good palliation of symptoms has been achieved in all survivors. These approaches fulfill the criteria for the surgical management of these difficult tumors by allowing excellent exposure, safe repetition if required, satisfactory palliation, and acceptable morbidity.


Neurosurgery | 1993

Chondrosarcoma of the Skull BaseA Series of Eight Cases

S. R. Stapleton; P. R. Wilkins; Daniel J. Archer; David Uttley

: Chondrosarcomas of the skull base are indolent, locally invasive tumors with a marked tendency to recur. Surgery is the mainstay of treatment because these tumors are generally resistant to other forms of treatment. A surgical approach with wide access to the skull base and one that is easily repeatable is required, because recurrence is common. We have used the LeFort I maxillotomy or mobilization of the zygoma at the time of craniotomy to obtain wide access to the skull base in eight cases of chondrosarcoma. Three patients have undergone subsequent procedures by us for recurrent disease. One patient died 30 days after the operation, and one has required an open repair of a cerebrospinal fluid leak. Good palliation of symptoms has been achieved in all survivors. These approaches fulfill the criteria for the surgical management of these difficult tumors by allowing excellent exposure, safe repetition if required, satisfactory palliation, and acceptable morbidity.


British Journal of Neurosurgery | 1995

Haemangiopericytoma: a clinical and radiological comparison with atypical meningiomas

D. Uttley; A. C. Clifton; P. R. Wilkins

A small number of haemangiopericytomas (HPCs) are compared with a group of cases labelled as atypical meningiomas (AMs) extracted from our records over a 10-year period. There was close convergence between the two groups in terms of clinical presentation. Radiologically, they were quite different. HPCs subjected to angiography demonstrated a major vascular supply from branches of the internal carotid or vertebral arteries, whereas this was not a feature of the meningioma group. Half the HPCs arose from the lateral petrosal attachment of the tentorium; all the meningiomas were parasagittal. The HPCs did not prove to be more formidable technical challenges than the meningiomas: the operative blood loss was much the same in both. The same number of recurrences and deaths occurred in the two groups at approximately the same interval during the follow-up period, making both conditions equally grave in terms of prognosis.


British Journal of Neurosurgery | 1994

Prolactinomas in men masquerading as invasive skull base tumours

Raymond J. Cook; David Uttley; P. R. Wilkins; Daniel J. Archer; Bryan A. Bell

Four giant prolactin-secreting tumours invading the skull base are described. All of them occurred in men. The presenting features were sufficiently diverse to be clinically misleading. We advocate the estimation of prolactin levels before embarking on complicated skull base surgery in men where doubt remains regarding the diagnosis after clinical and radiological study.


NMR in Biomedicine | 2006

Development of a Decision Support System for Diagnosis and Grading of Brain Tumours using in-vivo Magnetic Resonance Single Voxel Spectra

Anne Rosemary Tate; Joshua Underwood; Dionisio Acosta; Margarida Julià-Sapé; Carles Majós; Àngel Moreno-Torres; Franklyn A. Howe; Marinette van der Graaf; Virginie Lefournier; Mary Murphy; Alison Loosemore; Christophe Ladroue; Pieter Wesseling; Jean Luc Bosson; Miquel E. Cabañas; Arjan W. Simonetti; Witold Gajewicz; Jorge Calvar; Antoni Capdevila; P. R. Wilkins; B. Anthony Bell; Chantal Rémy; Arend Heerschap; Des Watson; John R. Griffiths; Carles Arús


British Journal of Neurosurgery | 2002

Neuropathological diagnostic accuracy

Mary Murphy; Alison Loosemore; I. Ferrer; Pieter Wesseling; P. R. Wilkins; B. A. Bell

Collaboration


Dive into the P. R. Wilkins's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel J. Archer

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dan Agranoff

University College London

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge